| for the Year Ended 31 Janua 2 |
023 | |||||
|---|---|---|---|---|---|---|
| 2023 | 2022 | |||||
| Unrestricted | Restricted | Total | Total | |||
| Notes | fundf | funds f |
funds f |
fundsf | ||
| INCOME AND ENDOWMENTS | FROM | |||||
| Donations and legacies |
51 | (1) | 50 | |||
| Charitable activities |
||||||
| Charitable activities |
200,798 | 200,798 | 187,097 | |||
| Investment income |
3 | 96,047 | 96,047 | 32,799 | ||
| Total | 96,098 | 200,797 | 296,895 | 219,895 | ||
| EXPENDITURE ON | ||||||
| Raising funds | 4 | 10,650 | 10,650 | 9,029 | ||
| Charitable activities |
||||||
| Charitable activities |
62485 | 219663 | 282148 | 174259 | ||
| Total | 73,135 | 219,663 | 292,798 | 183,288 | ||
| Net gains/(losses) on investments |
~)9,736) | ~)9736) | 9,083 | |||
| NET INCOME/(EXPENDITURE) | 3,227 | (18,866) | (15,639) | 45,690 | ||
| RECONCILIATION OF FUNDS |
||||||
| Total funds brought forward |
1,085,987 | 533,180 | 1,619,167 | 1,573,477 | ||
| TOTAL FUNDS CARRIED FORWARD | 1,089,214 | 514,314 | 1 603528 | 1,619,167 |
| Balance Sheet |
|||||
|---|---|---|---|---|---|
| ~31 4 2023 |
|||||
| 2023 | 2022 | ||||
| Unrestricted | Restricted | Total | Total | ||
| Notes | fund f |
funds f |
fundsf | fundsf | |
| FIXEDASSETS | |||||
| Investments | 8 | 215,963 | 215,963 | 243,431 | |
| CURRENT ASSETS | |||||
| Debtors | 9 | 541,652 | 377,541 | 919,193 | 756,837 |
| Cash at bank | 334296 | 421 954 | 756 242 | 818349 | |
| 1175940 | 799495 | 1,675,435 | 1,575,186 | ||
| CREDITORS | |||||
| Amounts falling due within one year |
10 | (2,689) | (285,181) | (287,870) | (199,450) |
| NET CURRENT ASSETS | 873,251 | 514,314 | 1,387,565 | 1,375,736 | |
| TOTAL ASSETS LESSCURRENT | |||||
| LIABILITIES | 1,089,214 | 514,314 | 1,603,528 | 1,619,167 | |
| NET ASSETS | 1,089,214 | 514,314 | 1 603528 | 1 619,167 | |
| FUNDS | |||||
| Unrestricted funds |
1,089,214 | 1,085,987 | |||
| Restricted funds | 514,314 | 533,180 | |||
| TOTAL FUNDS | 1 603528 | 1,619,167 |
| Consolidation | Consolidation | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| In the opinion | ofthe | directors, the | company | and its | subsidiary | undertakings | comprise a small group. The company | ||||||
| has therefore | taken | advantage | of the exemption | provided | by | Section | 398 of the | Companies | Act | 2006 not to | |||
| prepare | group | accounts. | |||||||||||
| INVESTMENT | INCOME | ||||||||||||
| 2023 | 2022 | ||||||||||||
| Unrestricted | Restricted | Total | Total | ||||||||||
| funds 6 |
fundsf | funds | fundsf | ||||||||||
| Diwdend | income | 96047 | 96047 | 32799 | |||||||||
| RAISING FUNDS | |||||||||||||
| Raising | donations | and | legacies | ||||||||||
| 2023 | 2022 | ||||||||||||
| Unrestricted | Restricted | Total | Total | ||||||||||
| funds | fundsf | funds | fundsf | ||||||||||
| Support | costs | 6 537 | |||||||||||
| Investment management |
costs | ||||||||||||
| 2023 | 2022 | ||||||||||||
| Unrestricted | Restricted | Total | Total | ||||||||||
| fundsf | fundsf | fundsf | fundsf | ||||||||||
| Support | costs | 1 721 | 1 721 | 2492 | |||||||||
| Aggregate amounts |
10650 | 10650 | 9029 |
| 2023 | 2022 |
|---|---|
| 13 | 13 |
| Unrestricted | Restricted | Total | |||
|---|---|---|---|---|---|
| fund | funds | funds | |||
| 6 | 6 | 6 | |||
| INCOME AND ENDOWMENTS | FROM | ||||
| Donations and legacies |
|||||
| Charitable activities |
|||||
| Charitable activities |
187,097 | 187,097 | |||
| Investment income |
32799 | 32 799 | |||
| Total | 32,799 | 187,096 | 219,895 | ||
| EXPENDITURE ON | |||||
| Raising funds | 9,029 | 9,029 | |||
| Charitable activities |
|||||
| Charitable activities |
2,652 | 171,607 | 174,259 | ||
| Total | 11,681 | 171,607 | 183,288 | ||
| Net gains on investments | 9,083 | 9,083 | |||
| NET INCOME | 30,201 | 15,489 | 45,690 | ||
| RECONCILIATION | OF FUNDS | ||||
| Total funds brought |
forward | 1,055,786 | 517,691 | 1,573,477 | |
| TOTAL FUNDS CARRIED FORWARD | 1085987 | 533180 | 1619167 |
| Shares | in | in | ||||||
|---|---|---|---|---|---|---|---|---|
| gl'oup | Listed | Other | ||||||
| undertakings | investments f |
investments f. |
Totalsf | |||||
| MARKET VALUE | ||||||||
| At 1 February 2022 | 221,061 | 22,369 | 243,431 | |||||
| Additions | 25,570 | 25,570 | ||||||
| Disposals Revaluations |
(33,302) ~17979) |
~1757) | (33,302) ~19736) |
|||||
| At 31 January 2023 | 195,350 | 20,612 | 215,963 | |||||
| NET BOOK VALUE | ||||||||
| At 31 January 2023 | 195350 | 20612 | 215963 | |||||
| At 31 January 2022 | 221 061 | 22 369 | 243 431 | |||||
| There were no investment | assets outside the UK. | |||||||
| Cost or valuation | at 31 January 2023 is represented | by: | ||||||
| Shares | in | |||||||
| group | I isted | Other | ||||||
| undertakings f |
investments f |
investmentsf | Totalsf | |||||
| Valuation in 2023 |
1 | 195350 | 20612 | 215963 |
| CREDITORS: AMOU | NTS | F | ALLING DUE WITHIN O | NE YEAR | ||
|---|---|---|---|---|---|---|
| 2023f | 2022 f |
|||||
| Amounts owed to group undertakings |
285,181 | 197,022 | ||||
| Accruals and deferred | income | 2 689 | 2428 | |||
| 287 870 | 199450 | |||||
| MOVEMENT IN FUNDS |
||||||
| Net | ||||||
| movement | At | |||||
| At 1/2/22 | in funds f |
31/1/23 f |
||||
| Unrestricted funds |
||||||
| General fund |
1,085,987 | 3,227 | 1,089,214 | |||
| Restricted funds | ||||||
| National Audit Programmes |
(573) | (75) | (648) | |||
| NHS Priorities Scheme | (13,548) | (13,548) | ||||
| National Liragutide & |
Exenatide | |||||
| Scheme | 22,540 | 22,540 | ||||
| Revise Research Project | (228) | (228) | ||||
| Degludec Nationwide |
Audit | 12,516 | 12,516 | |||
| Nationwide Audit Therapies |
Audit fund | (42) | (42) | |||
| Canagliflozin audit |
44,847 | (13,548) | 31,299 | |||
| Libre audit | 130,876 | 25,252 | 156,128 | |||
| Testosterone audit |
41,479 | 53,633 | 95,112 | |||
| Semaglutide audit |
284,201 | (14,300) | 269,901 | |||
| Empagliflozin audit |
(3,185) | (13,548) | (16,733) | |||
| ABCD Research fund | (72,473) | (72,473) | ||||
| COVID Diabetes National |
Audit | (18,405) | (960) | (19,365) | ||
| Omnipod Audit TOTAL FUNDS |
18,884 533155 1 619.161 |
30,971 ~48866) ~)5639) |
49,855 514314 1 683 528 |
| Net movement in fund |
s, in |
cl | ude | d in the above |
are as follows: | |||
|---|---|---|---|---|---|---|---|---|
| Incoming | Resources | Gains and | Movement | |||||
| resourcesf | expendedf | lossesf | in fundsf | |||||
| Unrestricted funds |
||||||||
| General fund |
96,098 | (73,135) | (19,736) | 3,227 | ||||
| Restricted funds | ||||||||
| National Audit Programmes |
(75) | (75) | ||||||
| NHS Priorities Scheme | (13,548) | (13,548) | ||||||
| Revise Research Project | (228) | (228) | ||||||
| Nationwide Audit Therapies |
Audit fund | (42) | (42) | |||||
| Canagliflozin audit |
(13,548) | (13,548) | ||||||
| Libre audit | 69,200 | (43,948) | 25,252 | |||||
| Testosterone audit |
82,798 | (29,165) | 53,633 | |||||
| Semaglutide audit |
(1) | (14,299) | (14,300) | |||||
| Empagliflozin audit |
(13,548) | (13,548) | ||||||
| ABCD Research fund | (72,473) | (72,473) | ||||||
| COVID Diabetes National Omnipod Audit TOTAL FUNDS |
Audit | 48 800 200,797 296895 |
(960) ~17829) ~219,663) ~292798) |
~19736) | (960) ~30 971 ~18,866) ~15639) |
|||
| Comparatives for movement |
in funds | |||||||
| Net | ||||||||
| movement | At | |||||||
| At 1/2/21f | in fundsf | 31/1/22 f |
||||||
| Unrestricted funds |
||||||||
| General fund |
1,055,786 | 30,201 | 1,085,987 | |||||
| Restricted funds | ||||||||
| National Audit Programmes |
1,014 | (1,587) | (573) | |||||
| National I iragutide 8 |
Exenatide | |||||||
| Scheme | 29,489 | (6,949) | 22,540 | |||||
| Degludec Nationwide |
Audit | 19,465 | (6,949) | 12,516 | ||||
| Canagliflozin audit |
51,796 | (6,949) | 44,847 | |||||
| Libre audit | 122,964 | 7,912 | 130,876 | |||||
| Testosterone audit |
48,428 | (6,949) | 41,479 | |||||
| Semaglutide audit |
230,771 | 53,430 | 284,201 | |||||
| Empagliflozin audit |
3,764 | (6,949) | (3,185) | |||||
| COVID Diabetes National |
Audit | 10,000 | (28,405) | (18,405) | ||||
| Omnipod Audit |
18884 | 18884 | ||||||
| 517,691 | 15,489 | 533,180 | ||||||
| TOTAL FUNDS | 1,573,477 | 45 695 | 1,619,167 |
| Comparative net m |
ove | men | t | in funds, included in th |
e above are | as | foll | ows | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Incoming | Resources | Gains and | Movement | |||||||
| resourcesf | expended f |
losses f |
in fundsf | |||||||
| Unrestricted funds |
||||||||||
| General fund |
32,799 | (11,681) | 9,083 | 30,201 | ||||||
| Restricted funds | ||||||||||
| National Audit Programmes National Liragutide 8 Exenatide |
(1,587) | (1,587) | ||||||||
| Scheme | (6,949) | (6,949) | ||||||||
| Degludec Nationwide |
Audit | (6,949) | (6,949) | |||||||
| Canagliflozin audit |
(6,949) | (6,949) | ||||||||
| Libre audit | 65,098 | (57,186) | 7,912 | |||||||
| Testosterone audit |
(6,949) | (6,949) | ||||||||
| Semaglutide audit |
60,998 | (7,568) | 53,430 | |||||||
| Empagliflozin audit |
(6,949) | (6,949) | ||||||||
| COVID Diabetes National Omnipod Audit |
Audit | 61 000 | (28,405) ~42 116) |
(28,405) 18884 |
||||||
| 187,096 | ~171,607) | 15,489 | ||||||||
| TOTAL FUNDS | 219,895 | ~183288) | 9,083 | 45 690 | ||||||
| A current year 12 months | and prior year 12 months | combined | position | is as follows: | ||||||
| Net | ||||||||||
| movement | At | |||||||||
| At 1/2/21f | in funds f. |
31/1/23 | ||||||||
| Unrestricted funds |
||||||||||
| General fund |
1,055,786 | 33,428 | 1,089,214 | |||||||
| Restricted funds | ||||||||||
| National Audit Programmes |
1,014 | (1,662) | (648) | |||||||
| NHS Pnonties Scheme | (13,548) | (13,548) | ||||||||
| National Liragutide |
& | Exenatide | ||||||||
| Scheme | 29,489 | (6,949) | 22,540 | |||||||
| Revise Research Project | (228) | (228) | ||||||||
| Degludec Nationwide |
Audit | 19,465 | (6,949) | 12,516 | ||||||
| Nationwide Audit Therapies |
Audit fund | (42) | (42) | |||||||
| Canagliflozin audit |
51,796 | (20,497) | 31,299 | |||||||
| Libre audit | 122,964 | 33,164 | 156,128 | |||||||
| Testosterone audit |
48,428 | 46,684 | 95,112 | |||||||
| Semaglutide audit |
230,771 | 39,130 | 269,901 | |||||||
| Empagliflozin audit |
3,764 | (20,497) | (16,733) | |||||||
| ABCD Research fund | (72,473) | (72,473) | ||||||||
| COVID Diabetes National |
Audit | 10,000 | (29,365) | (19,365) | ||||||
| Omnipod Audit |
49 1155 517691 ~33177 |
49,855 514314 |
||||||||
| TOTAL FUNDS | I 573.477 | 30051 | 1 603 525 |
as follows: |
, |
||||||
|---|---|---|---|---|---|---|---|
| Incoming | Resources | Gains and | Movement | ||||
| resources | expendedf | losses | in funds | ||||
| Unrestricted funds |
|||||||
| General fund |
128,897 | (84,816) | (10,653) | 33,428 | |||
| Restricted funds | |||||||
| National Audit Programmes |
(1,662) | (1,662) | |||||
| NHS Priorities Scheme | (13,548) | (13,548) | |||||
| National Liragutide & |
Exenatide | ||||||
| Scheme | (6,949) | (6,949) | |||||
| Revise Research Project | (228) | (228) | |||||
| Degludec Nationwide |
Audit | (6,949) | (6,949) | ||||
| Nationwide Audit Therapies |
Audit fund | (42) | (42) | ||||
| Canagliflozin audit |
(20,497) | (20,497) | |||||
| I ibre audit | 134,298 | (101,134) | 33,164 | ||||
| Testosterone audit |
82,798 | (36,114) | 46,684 | ||||
| Semaglutide audit |
60,997 | (21,867) | 39,130 | ||||
| Empagliflozin audit |
(20,497) | (20,497) | |||||
| ABCD Research fund | (72,473) | (72,473) | |||||
| COVID Diabetes National Omnipod Audit TOTAL FUNDS |
Audit | 109,800 387,893 516,790 |
(29,365) ~59945) ~391,270) ~476,086) |
~10,653) | (29,365) 49 855 ~3,377) 30,051 |